Publications by authors named "Andrew D J Pearson"

99Publications

Reply to K. Beiske et al.

J Clin Oncol 2020 Nov 15;38(31):3720-3721. Epub 2020 Sep 15.

Elizabeth Sokol, MD, Department of Pediatrics and Lurie Children's Hospital, Northwestern University, Chicago, IL; Ami V. Desai, MD, MSCE, and Mark A. Applebaum, MD, Department of Pediatrics and Comer Children's Hospital, University of Chicago, Chicago, IL; Dominique Valteau-Couanet, MD, PhD, Institute Gustave Roussy, Villejuif, France; Julie R. Park, MD, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA; Andrew D.J. Pearson, MD, Paediatric Drug Development, Children and Young People's Unit, Royal Marsden Hospital, London, UK; Gudrun Schleiermacher, MD, PhD, Department of Pediatric, Adolescents, and Young Adults Oncology and INSERM U830, Institut Curie, Paris, France; Meredith S. Irwin, MD, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; Michael Hogarty, MD, Department of Pediatrics, University of Pennsylvania, Philadelphia, PA; Arlene Naranjo, PhD, Department of Biostatistics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL; Samuel Volchenboum, MD, PhD, and Susan L. Cohn, MD, Department of Pediatrics and Comer Children's Hospital, University of Chicago, Chicago, IL; and Wendy B. London, PhD, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.02147DOI Listing
November 2020

The RACE to accelerate drug development for children with cancer.

Lancet Child Adolesc Health 2020 10 18;4(10):714-716. Epub 2020 Aug 18.

ACCELERATE, Europe; Gustave Roussy Cancer Centre, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-4642(20)30247-9DOI Listing
October 2020

The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.

Pediatr Blood Cancer 2020 08 30;67(8):e28359. Epub 2020 May 30.

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28359DOI Listing
August 2020

Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial.

Pediatr Blood Cancer 2019 04 5;66(4):e27565. Epub 2018 Dec 5.

Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (retired).

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pbc.27565
Publisher Site
http://dx.doi.org/10.1002/pbc.27565DOI Listing
April 2019

Outcome of children and adolescents with central nervous system tumors in phase I trials.

J Neurooncol 2018 Mar 13;137(1):83-92. Epub 2017 Dec 13.

Pediatric and Adolescent Drug Development, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust - Paediatric Offices, Downs Road, Sutton, SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2698-zDOI Listing
March 2018

Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.

Eur J Cancer 2017 11 19;86:275-284. Epub 2017 Oct 19.

Gustave Roussy, Biostatistics and Epidemiology Unit, Villejuif, France; INSERM U1018, CESP, Univ. Paris-Sud, Univ. Paris-Saclay, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.09.015DOI Listing
November 2017

In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.

PLoS One 2017 13;12(7):e0180263. Epub 2017 Jul 13.

Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0180263PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509135PMC
September 2017

Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.

Eur J Cancer 2016 07 10;62:9-17. Epub 2016 May 10.

Department of Pediatric and Adolescent Oncology, Gustave Roussy, Univ. Paris-Sud, 114, rue Edouard Vaillant, 94805 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.03.084DOI Listing
July 2016

Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.

Nucl Med Commun 2016 May;37(5):466-72

aChildren's and Young Persons Unit bJoint Department of Physics, Institute of Cancer Research, Royal Marsden NHS Foundation Trust cDepartment of Nuclear Medicine, The Royal Marsden Hospital, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000000470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819901PMC
May 2016

Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.

Mol Oncol 2016 Apr 19;10(4):538-52. Epub 2015 Nov 19.

Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, United Kingdom; School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2015.11.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423144PMC
April 2016

Children's clinical cancer trials: what needs to change to allow children access to new cancer drugs?

Expert Rev Clin Pharmacol 2015 24;8(6):665-7. Epub 2015 Aug 24.

c 3 Division of Clinical Studies, The Institute of Cancer Research , London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2015.1077699DOI Listing
June 2016

Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

J Clin Oncol 2015 Sep 24;33(27):3008-17. Epub 2015 Aug 24.

Navin R. Pinto, Mark A. Applebaum, Samuel L. Volchenboum, and Susan L. Cohn, Comer Children's Hospital, University of Chicago, Chicago, IL; Katherine K. Matthay, University of California San Francisco (UCSF) Benioff Children's Hospital, UCSF School of Medicine, San Francisco, CA; Wendy B. London, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Peter F. Ambros, Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna, Austria; Akira Nakagawara, Saga Medical Center Koseikan, Saga, Japan; Frank Berthold, Children's Hospital, University of Cologne, Koln, Germany; Gudrun Schleiermacher, Institut Curie, Paris; Dominique Valteau-Couanet, Gustave Roussy, Villejuif, France; Julie R. Park, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; and Andrew D.J. Pearson, Institute of Cancer Research and Royal Marsden Hospital, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/27/3008.full.pdf
Web Search
http://200.40.135.66:90/toc/0873/2015/0873-20150920-27-07.pd
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.4648
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.4648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567703PMC
September 2015

Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma.

J Pediatr Hematol Oncol 2015 Apr;37(3):e150-3

*Children and Young People's Unit †Department of Nuclear Medicine & PET/CT, The Royal Marsden NHS Foundation Trust ‡Divisions of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK §Clinical Research Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000000308DOI Listing
April 2015

Childhood extracranial neoplasms: the role of imaging in drug development and clinical trials.

Pediatr Radiol 2015 Oct 5;45(11):1600-15. Epub 2015 Jun 5.

Paediatric Drug Development Unit, Children and Young People's Unit, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, SM2 5PT, Surrey, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s00247-015-3342
Web Search
http://link.springer.com/10.1007/s00247-015-3342-8
Publisher Site
http://dx.doi.org/10.1007/s00247-015-3342-8DOI Listing
October 2015

Targeted approaches to childhood cancer: progress in drug discovery and development.

Expert Opin Drug Discov 2015 May 3;10(5):483-95. Epub 2015 Apr 3.

The Royal Marsden NHS Foundation Trust, Children and Young People's Unit , Sutton, Surrey, SM2 5PT , UK +44 0 20 8915 6161 ;

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/17460441.2015.10
Publisher Site
http://dx.doi.org/10.1517/17460441.2015.1025745DOI Listing
May 2015

Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

J Clin Oncol 2014 Oct 25;32(28):3169-76. Epub 2014 Aug 25.

Kieuhoa T. Vo, Katherine K. Matthay, John Neuhaus, and Steven G. DuBois, Benioff Children's Hospital and University of California, San Francisco, San Francisco; Doug Miniati, Kaiser Permanente Medical Center, Roseville, CA; Wendy B. London, Children's Oncology Group Statistics and Data Center and Dana-Farber Children's Hospital Cancer Center, Boston, MA; Barbara Hero, Children's Hospital, University of Cologne, Köln, Germany; Peter F. Ambros, Children's Cancer Research Institute, St Anne Kinderkrebsforschung, Vienna, Austria; Akira Nakagawara, Chiba Cancer Center Research Institute and Chiba University, Chiba, Japan; Kate Wheeler, Oxford Children's Hospital, Oxford; Andrew D.J. Pearson, Institute of Cancer Research and Royal Marsden Hospital, Surrey, United Kingdom; Susan L. Cohn, The University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/08/25/JCO.2014.56
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.56.1621
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.1621DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171360PMC
October 2014

Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.

Pediatr Blood Cancer 2014 Nov 7;61(11):1932-9. Epub 2014 Jul 7.

Department of Hematology/Oncology, Children's National Medical Center, Washington, District of Columbia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.25134DOI Listing
November 2014

Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma.

PLoS One 2014 25;9(3):e92886. Epub 2014 Mar 25.

Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092886PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965493PMC
December 2014

Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.

J Clin Oncol 2014 Apr 24;32(12):1228-35. Epub 2014 Mar 24.

Daniel A. Morgenstern and Meredith S. Irwin, Hospital for Sick Children and University of Toronto; Derek Stephens, Hospital for Sick Children, Toronto, ON, Canada; Daniel A. Morgenstern, Great Ormond Street Hospital for Children National Health Service (NHS) Foundation Trust, London; Andrew D.J. Pearson, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; Wendy B. London, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Samuel L. Volchenboum and Susan L. Cohn, University of Chicago, Chicago, IL; Barbara Hero, University Children's Hospital, Köln, Germany; Andrea Di Cataldo, University of Catania, Catania, Italy; Akira Nakagawara, Chiba University School of Medicine, Chiba, Japan; Hiroyuki Shimada, University of Southern California at Los Angeles, Los Angeles; Katherine K. Matthay, University of California at San Francisco, San Francisco, CA; and Peter F. Ambros, St. Anna Kinderkrebsforschung, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.6342DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876342PMC
April 2014

MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance.

Curr Drug Targets 2014 Jan;15(1):114-23

The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/13894501113149990194DOI Listing
January 2014

Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience.

J Pediatr Hematol Oncol 2014 Apr;36(3):218-23

*Pediatric Drug Development Unit, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust §Pediatric Drug Development Team, Divisions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research, Sutton †Pediatric Oncology Department, Great Ormond Street Hospital ‡Institute of Child Health, University College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000000003DOI Listing
April 2014

Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaboration.

AMIA Jt Summits Transl Sci Proc 2013 18;2013:103. Epub 2013 Mar 18.

Department of Pediatrics, University of Chicago, Chicago, IL; ; Center for Research Informatics, University of Chicago, Chicago, IL;

View Article

Download full-text PDF

Source
December 2013

At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.

Br Med Bull 2013 7;108:173-88. Epub 2013 Nov 7.

Paediatric Drug Development Team, Di visions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bmb/ldt033DOI Listing
July 2014

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.

Clin Cancer Res 2013 Nov 21;19(21):5814-21. Epub 2013 Aug 21.

Authors' Affiliations: Paediatric Solid Tumour Biology and Therapeutics Team, Division of Clinical Studies, The Institute of Cancer Research; Children's and Young People's Unit Royal Marsden NHS Trust, Sutton; and Unit of Molecular Haematology and Cancer Biology, Institute of Child Health, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0680DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818140PMC
November 2013

How can attrition rates be reduced in cancer drug discovery?

Expert Opin Drug Discov 2013 Apr 4;8(4):363-8. Epub 2013 Feb 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17460441.2013.768984DOI Listing
April 2013

About the benefits of immunotherapy for high-risk neuroblastoma.

J Clin Oncol 2013 Feb 7;31(5):649-50. Epub 2013 Jan 7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.4080DOI Listing
February 2013

Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience.

Pediatr Blood Cancer 2013 Jul 31;60(7):1135-40. Epub 2012 Dec 31.

Children and Young People's Unit, The Royal Marsden NHS Foundation Trust-The Institute of Cancer Research, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pbc.24452
Publisher Site
http://dx.doi.org/10.1002/pbc.24452DOI Listing
July 2013

Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.

Radiology 2013 Jan 20;266(1):130-40. Epub 2012 Nov 20.

Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, Surrey SM2 5NG, England.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.12120128DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298658PMC
January 2013

Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project.

Eur J Cancer 2012 May 1;48(8):1185-91. Epub 2011 Dec 1.

Department of Paediatrics, Division of Haematology and Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049110087
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2011.10.037DOI Listing
May 2012

Preclinical drug development for childhood cancer.

Expert Opin Drug Discov 2011 Jan 24;6(1):49-64. Epub 2010 Nov 24.

The Royal Marsden NHS Foundation Trust, Children and Young People's Unit, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17460441.2011.537652DOI Listing
January 2011

MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.

Cancer Res 2010 Nov 8;70(22):9243-52. Epub 2010 Oct 8.

Paediatric Oncology, and Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, and Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-10-1250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935452PMC
November 2010

Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.

Pediatr Blood Cancer 2010 Jul;54(7):983-9

Department of Paediatric and Adolescent Oncology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.22364DOI Listing
July 2010

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.

Clin Cancer Res 2010 Feb 9;16(4):1108-18. Epub 2010 Feb 9.

Department of Cellular Pathology, Northern Institute for Cancer Research, Royal Victoria Infirmary, Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1865DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2842933PMC
February 2010

Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.

Eur J Cancer 2009 Dec 21;45(18):3213-9. Epub 2009 Oct 21.

Department of Paediatric and Adolescent Oncology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S095980490900514
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2009.06.032DOI Listing
December 2009

Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients.

Cancer Chemother Pharmacol 2010 May 23;65(6):1057-66. Epub 2009 Aug 23.

Northern Institute for Cancer Research, Medical School, Newcastle University, Paul O'Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-009-1111-9DOI Listing
May 2010

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.

Lancet Oncol 2008 Mar;9(3):247-56

Children's Department, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(08)70069-XDOI Listing
March 2008

p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma.

Cell Cycle 2007 Nov 10;6(21):2685-96. Epub 2007 Aug 10.

Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.6.21.4853DOI Listing
November 2007

APC and CTNNB1 mutations are rare in sporadic ependymomas.

Cancer Genet Cytogenet 2006 Jul;168(2):158-61

Northern Institute for Cancer Research, University of Newcastle, The Medical School, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S016546080600148
Publisher Site
http://dx.doi.org/10.1016/j.cancergencyto.2006.02.019DOI Listing
July 2006

Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.

Cancer Res 2006 Feb;66(4):2138-45

Northern Institute for Cancer Research, University of Newcastle Upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-2623DOI Listing
February 2006

Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: how much do we really know?

Pediatr Blood Cancer 2006 Jun;46(7):723-7

Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.20463DOI Listing
June 2006

Regions syntenic to human 17q are gained in mouse and rat neuroblastoma.

Genes Chromosomes Cancer 2004 Jun;40(2):158-63

Institute of Human Genetics, International Centre for Life, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20031DOI Listing
June 2004

Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma.

Clin Cancer Res 2004 Jan;10(2):455-60

Department of Child Health, Yorkhill National Health Service Trust, Glasgow, United Kongdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.ccr-0844-03DOI Listing
January 2004

Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior.

Cancer 2004 Jan;100(2):390-7

Department of Pathology, Faculty of Medicine, Medical and Health Sciences Center, University of Pécs, Szigeti út 12, H-7643 Pécs, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20005DOI Listing
January 2004

Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry.

J Chromatogr B Analyt Technol Biomed Life Sci 2003 Oct;795(2):237-43

Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1570-0232(03)00573-7DOI Listing
October 2003

The p53 pathway and its inactivation in neuroblastoma.

Cancer Lett 2003 Jul;197(1-2):93-8

Cancer Research Unit, The Medical School, University of Newcastle, Newcastle-upon-Tyne NE2 4HH, UK.

View Article

Download full-text PDF

Source
http://ac.els-cdn.com/S0304383503000880/1-s2.0-S030438350300
Web Search
http://search.proquest.com/openview/29c6d95b12d526bdda403463
Web Search
http://dx.doi.org/10.1016/s0304-3835(03)00088-0DOI Listing
July 2003

Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas.

J Neuropathol Exp Neurol 2003 Jun;62(6):627-32

Northern Institute for Cancer Research, University of Newcastle, Newcastle-upon-Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnen/62.6.627DOI Listing
June 2003

Retinoid signalling and gene expression in neuroblastoma cells: RXR agonist and antagonist effects on CRABP-II and RARbeta expression.

J Cell Biochem 2002 ;87(3):284-91

Department of Child Health, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcb.10310
Publisher Site
http://dx.doi.org/10.1002/jcb.10310DOI Listing
April 2004

Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development.

Cancer Res 2002 Oct;62(20):5906-11

Northern Institute for Cancer Research, The Medical School, University of Newcastle, Newcastle-upon-Tyne, NE2 4HH, United Kingdom.

View Article

Download full-text PDF

Source
October 2002

Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors.

Genes Chromosomes Cancer 2002 Aug;34(4):428-36

Institute of Human Genetics, International Centre for Life, University of Newcastle upon Tyne, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/gcc.10089
Publisher Site
http://dx.doi.org/10.1002/gcc.10089DOI Listing
August 2002

Retinoid X receptors and retinoid response in neuroblastoma cells.

J Cell Biochem 2002 ;86(1):67-78

Department of Endocrinology, Medical Molecular Biology Group, Medical School, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcb.10192
Publisher Site
http://dx.doi.org/10.1002/jcb.10192DOI Listing
December 2002

Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells.

Biochem Pharmacol 2002 Jan;63(2):207-15

Cancer Research Unit, Medical School, University of Newcastle-upon-Tyne, NE2 4HH, Newcastle-upon-Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-2952(01)00844-9DOI Listing
January 2002